Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer

BACKGROUND: Immunotherapies targeting the PD-1 checkpoint pathway have recently gained regulatory approval in numerous cancer types. With the widespread use of immune checkpoint therapies, varying patterns of responses and immune-related adverse events are being observed. CASE PRESENTATION: In this...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Immunother Cancer
Main Authors: Sweis, Randy F., Zha, Yuanyuan, Pass, Lomax, Heiss, Brian, Chongsuwat, Tara, Luke, Jason J., Gajewski, Thomas F., Szmulewitz, Russell
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5883337/
https://ncbi.nlm.nih.gov/pubmed/29618376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0334-x
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki